{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:09:30Z","timestamp":1790003370301,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,3,19]],"date-time":"2015-03-19T00:00:00Z","timestamp":1426723200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s00280-015-2717-8","type":"journal-article","created":{"date-parts":[[2015,3,18]],"date-time":"2015-03-18T16:33:09Z","timestamp":1426696389000},"page":"1089-1093","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia"],"prefix":"10.1007","volume":"75","author":[{"given":"Sophia Ingeborg","family":"Vang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjeld","family":"Schmiegelow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Frandsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Rosth\u00f8j","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Nersting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,19]]},"reference":[{"issue":"2","key":"2717_CR1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/leu.2009.251","volume":"24","author":"K Schmiegelow","year":"2010","unstructured":"Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Soderhall S et al (2010) Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 24(2):345\u2013354","journal-title":"Leukemia"},{"issue":"4","key":"2717_CR2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/ejh.12243","volume":"92","author":"B Lund","year":"2013","unstructured":"Lund B, Wesolowska-Andersen A, Lausen B, Borst L, Rasmussen KK, Muller K et al. (2013) Host genome variations and risk of infections during induction treatment for childhood acute lymphoblastic leukaemia. Eur J Haematol 92(4):321\u2013330","journal-title":"Eur J Haematol"},{"issue":"1","key":"2717_CR3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1559-0275-8-8","volume":"8","author":"J Nersting","year":"2011","unstructured":"Nersting J, Borst L, Schmiegelow K (2011) Challenges in implementing individualized medicine illustrated by antimetabolite therapy of childhood acute lymphoblastic leukemia. Clin Proteomics 8(1):8","journal-title":"Clin Proteomics"},{"issue":"2","key":"2717_CR4","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2011.08835.x","volume":"155","author":"TL Frandsen","year":"2011","unstructured":"Frandsen TL, Abrahamsson J, Lausen B, Vettenranta K, Heyman M, Behrentz M et al (2011) Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. Br J Haematol 155(2):244\u2013247","journal-title":"Br J Haematol"},{"issue":"7","key":"2717_CR5","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/sj.leu.2402990","volume":"17","author":"U Nygaard","year":"2003","unstructured":"Nygaard U, Schmiegelow K (2003) Dose reduction of coadministered 6-mercaptopurine decreases myelotoxicity following high-dose methotrexate in childhood leukemia. Leukemia 17(7):1344\u20131348","journal-title":"Leukemia"},{"issue":"5","key":"2717_CR6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s002800050405","volume":"37","author":"F Innocenti","year":"1996","unstructured":"Innocenti F, Danesi R, Di PA, Loru B, Favre C, Nardi M et al (1996) Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. Cancer Chemother Pharmacol 37(5):409\u2013414","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"2717_CR7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/MPH.0000000000000206","volume":"36","author":"K Schmiegelow","year":"2014","unstructured":"Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J (2014) Mercaptopurine\/methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol 36(7):503\u2013517","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"2717_CR8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00280-014-2613-7","volume":"75","author":"M Levinsen","year":"2014","unstructured":"Levinsen M, Rosthoj S, Nygaard U, Heldrup J, Harila-Saari A, Jonsson OG et al. (2014) Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity. Cancer Chemother Pharmacol 75(1):59\u201366","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2717_CR9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/sj.leu.2401986","volume":"15","author":"K Schmiegelow","year":"2001","unstructured":"Schmiegelow K, Bretton-Meyer U (2001) 6-Mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia. Leukemia 15(1):74\u201379","journal-title":"Leukemia"},{"issue":"9","key":"2717_CR10","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood.V93.9.2817","volume":"93","author":"MV Relling","year":"1999","unstructured":"Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE (1999) Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93(9):2817\u20132823","journal-title":"Blood"},{"issue":"8907","key":"2717_CR11","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S0140-6736(94)92400-7","volume":"343","author":"JS Lilleyman","year":"1994","unstructured":"Lilleyman JS, Lennard L (1994) Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 343(8907):1188\u20131190","journal-title":"Lancet"},{"issue":"12","key":"2717_CR12","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/0006-2952(88)90358-9","volume":"37","author":"JP Bokkerink","year":"1988","unstructured":"Bokkerink JP, Bakker MA, Hulscher TW, De Abreu RA, Schretlen ED (1988) Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages. Biochem Pharmacol 37(12):2321\u20132327","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2717_CR13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nrc2292","volume":"8","author":"P Karran","year":"2008","unstructured":"Karran P, Attard N (2008) Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 8(1):24\u201336","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2717_CR14","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/jcph.81","volume":"53","author":"MS Ebbesen","year":"2013","unstructured":"Ebbesen MS, Nersting J, Jacobsen JH, Frandsen TL, Vettenranta K, Abramsson J et al (2013) Incorporation of 6-thioguanine nucleotides into DNA during maintenance therapy of childhood acute lymphoblastic leukemia-the influence of thiopurine methyltransferase genotypes. J Clin Pharmacol 53(6):670\u2013674","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"2717_CR15","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/ejh.12097","volume":"90","author":"N Toft","year":"2013","unstructured":"Toft N, Birgens H, Abrahamsson J, Bernell P, Griskevicius L, Hallbook H et al (2013) Risk group assignment differs for children and adults 1\u201345\u00a0yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol. Eur J Haematol 90(5):404\u2013412","journal-title":"Eur J Haematol"},{"issue":"3","key":"2717_CR16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/clinchem\/44.3.551","volume":"44","author":"T Dervieux","year":"1998","unstructured":"Dervieux T, Boulieu R (1998) Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem 44(3):551\u2013555","journal-title":"Clin Chem"},{"issue":"881\u2013882","key":"2717_CR17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchromb.2011.11.032","volume":"15","author":"JH Jacobsen","year":"2012","unstructured":"Jacobsen JH, Schmiegelow K, Nersting J (2012) Liquid chromatography\u2013tandem mass spectrometry quantification of 6-thioguanine in DNA using endogenous guanine as internal standard. J Chromatogr B Anal Technol Biomed Life Sci 15(881\u2013882):115\u2013118","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"issue":"1","key":"2717_CR18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2307\/2531248","volume":"42","author":"SL Zeger","year":"1986","unstructured":"Zeger SL, Liang KY (1986) Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42(1):121\u2013130","journal-title":"Biometrics"},{"issue":"11","key":"2717_CR19","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1038\/sj.leu.2404404","volume":"20","author":"TV Skarby","year":"2006","unstructured":"Skarby TV, Anderson H, Heldrup J, Kanerva JA, Seidel H, Schmiegelow K (2006) High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia. Leukemia 20(11):1955\u20131962","journal-title":"Leukemia"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2717-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-015-2717-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2717-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:19:15Z","timestamp":1598833155000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-015-2717-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,19]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["2717"],"URL":"https:\/\/doi.org\/10.1007\/s00280-015-2717-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,19]]}}}